Le Lézard
Classified in: Health
Subjects: NPT, WOM, FVT, DEI

Susan G. Komen® MORE THAN PINK Walk Raises Money To Improve Outcomes For Breast Cancer Patients


HARTFORD, Conn., Sept. 22, 2022 /PRNewswire/ -- Susan G. Komen®, the world's leading breast cancer organization, will hold an in-person MORE THAN PINK Walk to raise critical funds that improve outcomes and support breast cancer patients throughout Connecticut. The Walk will be held on Saturday, Oct. 22, 2022, at Bushnell Park in Hartford.

"We look forward to creating a community for anyone impacted by breast cancer as we gather, in person, for this year's Walk. Funds raised from the MORE THAN PINK Walk will continue funding groundbreaking breast cancer research throughout the state and provide financial and emotional support for anyone in need," said Meg Staubley, Development Manager, Connecticut, at Susan G. Komen.

Komen is pleased to welcome the following sponsors this year: iHeartMedia, WFSB Channel 3, Pratt & Whitney, Premiere Partner, Arvinas, Jefferson Radiology, ShopRite, Gilead Sciences, Inc. and Force3 Pro Gear. Midstate Radiology Associates, LLC, is serving as the Care sponsor, supporting Komen's work to eliminate barriers to care and provide access to breast health services.

"Promoting positive change through community outreach is part of who we are. We feel it's our distinct responsibility to actively develop partnerships and give back in an impactful way within our communities," said Tom Cappas, Chief Operating Officer, Midstate Radiology Associates, LLC.

Participants can expect to enjoy the following at the Walk:

Komen MORE THAN PINK Walk
Bushnell Park
Hartford, Connecticut

October 22, 2022

7:30 AM Event Opens
9:00 AM Opening Ceremony
9:30 AM Walk Begins

Register Online
http://www.komen.org/connecticutwalk

About Susan G. Komen®

Susan G. Komen® is the world's leading nonprofit breast cancer organization, working to save lives and end breast cancer forever. Komen has an unmatched, comprehensive 360-degree approach to fighting this disease across all fronts and supporting millions of people in the U.S. and in countries worldwide. We advocate for patients, drive research breakthroughs, improve access to high-quality care, offer direct patient support and empower people with trustworthy information. Founded by Nancy G. Brinker, who promised her sister, Susan G. Komen, that she would end the disease that claimed Suzy's life, Komen remains committed to supporting those affected by breast cancer today, while tirelessly searching for tomorrow's cures. Visit komen.org or call 1-877 GO KOMEN. Connect with us on social at www.komen.org/contact-us/follow-us/.

CONTACT: Amanda DeBard
Susan G. Komen                      
(972) 701-2131
[email protected] 

SOURCE Susan G. Komen for the Cure


These press releases may also interest you

18 avr 2024
The 31st Canadian Cancer Society (CCS) Daffodil Ball, which took place this evening at Windsor Station in Montreal, raised $1,474,785 to fund innovative research projects and essential support programs for people living with cancer. The largest...

18 avr 2024
The report titled "Clinical Trials Matching Software Market by Functionality (Analytics & Reporting, Compliance Tracking, Data Management), Deployment (Cloud & Web Based, On-Premise), End-Use - Global Forecast 2024-2030" is now available on...

18 avr 2024
South Korea's biotechnology company Hyundai Bioscience (CEO Oh Sang-gi, www.hyundaibioscience.com) announced on April 15 that it would carry out global clinical tests aimed at treating all serotypes of Dengue virus infection....

18 avr 2024
The report titled "Progressive Familial Intrahepatic Cholestasis Treatment Market by Drug Type (Cholestyramine, Rifampicin, Ursodeoxycholic Acid), Distribution Channel (Hospital Pharmacies, Online Pharmacies, Retail Pharmacies), End-Users - Global...

18 avr 2024
RevolKa Ltd. (Norio Hamamatsu, President & CEO), a venture-backed biotech company providing a game-changing protein engineering technology platform and La Jolla Institute for Immunology (LJI) (Erica Saphire, President & CEO) agreed to start a...

18 avr 2024
Takeda (TSE:4502/NYSE:TAK) today announced that the U.S. Food and Drug Administration (FDA) has approved ENTYVIO® (vedolizumab) subcutaneous (SC) administration for maintenance therapy in adults with moderately to severely active Crohn's disease (CD)...



News published on and distributed by: